Advances in macrophage-targeting nanoparticles for the diagnosis and treatment of inflammatory bowel disease / 浙江大学学报·医学版
Journal of Zhejiang University. Medical sciences
;
(6): 785-794, 2023.
Artículo
en Inglés
| WPRIM
| ID: wpr-1009932
ABSTRACT
The pathogenesis of inflammatory bowel disease (IBD) is not fully elucidated. However, it has been considered that inflammatory macrophages may be involved in the imbalance of the intestinal mucosal immunity to regulate several signaling pathways, leading to IBD progression. The ratio of M1 to M2 subtypes of activated macrophages tends to increase in the inflamed intestinal section. There are challenges in the diagnosis and treatment of IBD, such as unsatisfactory specificity of imaging findings, low drug accumulation in the intestinal lesions, unstable therapeutic efficacy, and drug-related systemic toxicity. Recently developed nanoparticles may provide a new approach for the diagnosis and treatment of IBD. Nanoparticles targeted to macrophages can be used as contrast agents to improve the imaging quality or used as a drug delivery vector to increase the therapeutic efficiency of IBD. This article reviews the research progress on macrophage-targeting nanoparticles for the diagnosis and treatment of IBD to provide a reference for further research and clinical application.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Enfermedades Inflamatorias del Intestino
/
Nanopartículas
/
Mucosa Intestinal
/
Intestinos
/
Macrófagos
Límite:
Humanos
Idioma:
Inglés
Revista:
Journal of Zhejiang University. Medical sciences
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS